[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Health Agencies Update
April 22 2009

Metoclopramide Risks

JAMA. 2009;301(16):1647. doi:10.1001/jama.2009.537

The US Food and Drug Administration (FDA) is requiring a boxed warning on metoclopramide, a drug used to treat certain gastrointestinal tract conditions, to alert physicians and patients that prolonged use of the drug is known to cause movement disorders.

The agency is requiring the makers of the drug to update the labeling and create a risk mitigation strategy to make sure physicians and patients are aware of the risk. Metoclopramide is used as a short-term treatment in patients with treatment-resistant gastroesophageal reflux disease or in patients with diabetic gastroparesis. Despite a warning on the existing labeling that patients taking the drug for extended periods risk developing tardive dyskinesia, the agency continues to receive reports of this disorder emerging in patients who take metoclopramide.

First Page Preview View Large
First page PDF preview
First page PDF preview